Dianthus Therapeutics, Inc. (DNTH)
DNTH Stock Price Chart
Explore Dianthus Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze DNTH price movements and trends.
DNTH Company Profile
Discover essential business fundamentals and corporate details for Dianthus Therapeutics, Inc. (DNTH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Jun 2018
Employees
78.00
Website
https://dianthustx.comCEO
Marino Garcia
Description
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
DNTH Financial Timeline
Browse a chronological timeline of Dianthus Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.88, while revenue estimate is $576.00K.
Earnings released on 7 Aug 2025
EPS came in at -$0.88 falling short of the estimated -$0.86 by -2.33%, while revenue for the quarter reached $193.00K , missing expectations by -77.68%.
Earnings released on 12 May 2025
EPS came in at -$0.82 surpassing the estimated -$0.86 by +4.65%, while revenue for the quarter reached $1.16M , beating expectations by +44.13%.
Earnings released on 11 Mar 2025
EPS came in at -$0.81 surpassing the estimated -$0.85 by +4.71%, while revenue for the quarter reached $1.33M , beating expectations by +38.82%.
Earnings released on 7 Nov 2024
EPS came in at -$0.74 falling short of the estimated -$0.59 by -25.42%, while revenue for the quarter reached $2.17M , beating expectations by +157.31%.
Earnings released on 8 Aug 2024
EPS came in at -$0.51 falling short of the estimated -$0.50 by -2.00%, while revenue for the quarter reached $1.86M , beating expectations by +482.19%.
Earnings released on 9 May 2024
EPS came in at -$0.54 falling short of the estimated -$0.43 by -25.58%, while revenue for the quarter reached $874.00K , beating expectations by +90.00%.
Earnings released on 21 Mar 2024
EPS came in at -$0.71 surpassing the estimated -$1.11 by +36.04%, while revenue for the quarter reached $457.00K , beating expectations by +47.42%.
Earnings released on 9 Nov 2023
EPS came in at -$3.78 falling short of the estimated -$0.51 by -641.18%, while revenue for the quarter reached $924.00K , beating expectations by +125.37%.
Stock split effective on 12 Sept 2023
Shares were split 1 : 16 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 3 Aug 2023
EPS came in at -$0.05 surpassing the estimated -$0.19 by +73.68%, while revenue for the quarter reached $969.00K .
Earnings released on 30 Mar 2023
EPS came in at -$7.70 falling short of the estimated -$6.40 by -20.25%, while revenue for the quarter reached $476.00K .
Earnings released on 31 Dec 2022
EPS came in at -$2.67 surpassing the estimated -$4.10 by +34.89%, while revenue for the quarter reached $1.18M .
Earnings released on 30 Sept 2022
EPS came in at -$2.10 surpassing the estimated -$4.64 by +54.71%, while revenue for the quarter reached $1.17M .
Earnings released on 4 Aug 2022
EPS came in at -$4.70 surpassing the estimated -$5.44 by +13.63%.
Earnings released on 16 May 2022
EPS came in at -$6.24 .
Earnings released on 8 Mar 2022
EPS came in at -$5.25 falling short of the estimated -$5.09 by -3.15%.
Earnings released on 4 Nov 2021
EPS came in at -$4.76 .
Earnings released on 5 Aug 2021
EPS came in at -$5.04 .
Earnings released on 6 May 2021
EPS came in at -$5.76 .
Earnings released on 3 Mar 2021
EPS came in at -$5.99 .
Earnings released on 5 Nov 2020
EPS came in at -$5.86 .
DNTH Stock Performance
Access detailed DNTH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.